WaveMan
WaveMan · Company
TMDX · Transmedics Group, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

TMDX TransMedics (TMDX) Insider Trading, Ownership & Congress Trades

Medical Devices · Electromedical & electrotherapeutic apparatus · CIK 0001756262
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
213
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $42.6K priced

What the filings say about TMDX

Insiders, 180 days
-$613.3K net sold
1 buyer · 1 seller · 0% of sales under a 10b5-1 plan

TransMedics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, TransMedics Group, Inc. insiders sold a net $613.3K of stock across 375 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Weill David
Director
BUY
2026-09-14 SECtraded 2026-09-11
1,336
$109.1K
-19.8%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (1 buy, 8 sales), the last on Mar 4, 2026.
  • The trade is 8.2% of the 16,392 shares held after it.
  • No other insider bought within 30 days.
  • 213 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Weill David bought about $109.1K of TMDX on Sep 11, 2026; 213 funds added in the latest 13F quarter.
Gunderson Thomas J.
Director
SELL
2026-06-17 SECtraded 2026-06-15
9,624
$722.4K
-10.4%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 57.8% of the 16,642 shares held after it.
  • No other insider sold within 30 days.
  • 213 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Gunderson Thomas J. sold about $722.4K of TMDX on Jun 15, 2026; 213 funds added in the latest 13F quarter.
Lovell Stephanie
Director
SELL
2026-03-06 SECtraded 2026-03-04
1,193
$178.5K
-47.6%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Nov 23, 2022.
  • The trade is 41.6% of the 2,866 shares held after it.
  • 4 other insiders sold within 30 days.
  • 213 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Lovell Stephanie sold about $178.5K of TMDX on Mar 4, 2026; 4 other insiders sold within 30 days and 213 funds added in the latest 13F quarter.
Weill David
Director
SELL
2026-03-06 SECtraded 2026-03-04
3,571
$524.3K
-47.6%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (1 buy, 7 sales), the last on Dec 3, 2025.
  • The trade is 29.4% of the 12,134 shares held after it.
  • 4 other insiders sold within 30 days.
  • 213 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Weill David sold about $524.3K of TMDX on Mar 4, 2026; 4 other insiders sold within 30 days and 213 funds added in the latest 13F quarter.
Hernandez Gerardo
Chief Financial Officer
SELL
2026-03-04 SEC
1,324
$194.9K
-49.6%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Mar 2, 2026.
  • The trade is 9.0% of the 14,689 shares held after it.
  • 4 other insiders sold within 30 days.
  • 213 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Hernandez Gerardo sold about $194.9K of TMDX on Mar 4, 2026; 4 other insiders sold within 30 days and 213 funds added in the latest 13F quarter.
375 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 370 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$613.3K over 180 days
+$109.1K over 90 days
below 58% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
213 funds bought in last quarter
more than 85% of Medical Devices
Revenue
+37.1% year over year
more than 83% of Medical Devices
Margin
31.4% net margin
more than 98% of Medical Devices
Buybacks
no share repurchases reported
Short interest
25.5% of the float short (float per yahoo 2026-10-26) · 13.1 days to cover · settled 2026-09-30
the highest in Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch TMDX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-40.9%12M
-48%-23%+1%+26%2025-102025-122026-022026-042026-062026-082026-10 2025-11-17 · Hassanein Waleed H bought $1.0M2026-03-04 · Hernandez Gerardo sold $870.3K2026-06-15 · Gunderson Thomas J. sold $722.4K2025-12-03 · Weill David sold $693.2K2025-10-29 · Basile Edward M sold $540.3K2026-03-04 · Weill David sold $524.3K2025-11-25 · Ranganath Anil P. sold $435.7K2026-03-02 · Corcoran Nicholas sold $412.6K2026-03-04 · Hernandez Gerardo sold $194.9K2026-03-04 · Lovell Stephanie sold $178.5K2025-12-04 · Hernandez Gerardo sold $128.5K2026-03-02 · Ranganath Anil P. sold $120.2K2026-09-11 · Weill David bought $109.1K2026-03-02 · Hernandez Gerardo sold $52.2K
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns TMDX: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
5,596,549 sh
$371.7M
FMR LLC
5,133,328 sh
$341.0M
VANGUARD PORTFOLIO MANAGEMENT LLC
1,933,989 sh
$128.5M
VANGUARD CAPITAL MANAGEMENT LLC
1,497,600 sh
$99.5M
STATE STREET CORP
1,420,421 sh
$94.3M

Congress trades in TMDX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

TMDX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

TMDX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Moonvest ETF
$3.7M position · as of 2026-07-31
5.4%
Catalyst Insider Buying Fund
$867.8K position · as of 2026-06-30
3.9%
Miller Convertible Total Return ETF
$402.7K position · as of 2026-07-31
2.9%
F/m Emerald Life Sciences Innovation ETF
$2.8M position · as of 2026-05-31
2.7%
YieldMax(R) Ultra Option Income Strategy ETF
$19.1M position · as of 2026-07-31
2.6%
Global X HealthTech ETF
$612.0K position · as of 2026-05-31
2.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Waleed H. Hassanein, M.D.
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$10.9M
$26.2M
$2.4M
+511%
-1%
2024
$8.2M
$9.6M
$3.0M
+213%
-19%
2023
$6.8M
$12.8M
$2.5M
+297%
-18%
2022
$3.3M
$25.2M
$958.9K
+210%
-23%
2021
$7.4M
$5.2M
$1.4M
-4%
-4%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $613.3K sold by insiders over 180 days, 213 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWOMIRMDLUNG

TMDX financials

Revenue growth
+37.1%
XBRL, annual
Net margin
31.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$668.5M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+22.7%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$79.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.92x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
0.31x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
+36.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+12.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
effective tax rate -109%, not meaningful
Return on capital employed
+7.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
18.30x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$2.6B
market value at close 2026-10-26 on 2026-07-30 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2024-09-30
FCF yield
+3.2%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
0.18x
P/E over trailing EPS growth of 99%: four quarters to 2026-06-30 against the four to 2025-06-30
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$605.5M$441.5M$241.6M$93.5M
Gross profit$362.8M$262.1M$154.1M$65.3M
Operating income$108.6M$37.5M-$28.7M-$31.4M
Net income$190.3M$35.5M-$25.0M-$36.2M
EPS (diluted)4.871.01-0.77-1.23
Operating cash flow$192.8M$48.8M-$13.0M-$45.8M
Cashn/an/a$394.8M$201.2M
Long-term debt$452.8M$449.9M$447.1M$58.7M
SEC XBRL, fiscal years, as known on 2026-10-27

TMDX Stock Sonar score 6/7 axes

Find similar shapesCompare

TMDX ranks highest on profitability (89th percentile) and growth (88th), and lowest on insider conviction (46th), among Medical Devices peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
89
Inputs
  • Return on equity+36.3% · 96 pct, sector of 183
  • Return on assets+12.9% · 91 pct, sector of 214
  • Return on invested capitaleffective tax rate -109%, not meaningful
  • Return on capital employed+7.4% · 79 pct, sector of 188
Financial health
49
Inputs
  • Debt to equity0.92x · 21 pct, sector of 159
  • Cash flow to debt0.31x · 77 pct, sector of 150
Growth
88
Inputs
  • Revenue growth, YoY+37.1% · 83 pct, sector of 219
  • Backlog growth, YoY+100.0% · 92 pct, sector of 37
Insider conviction
46
Inputs
  • Net Form 4 buying (codes P and S), 180d-$613K · 40 pct, sector of 140
  • Insider buyers, 180d1 · 52 pct, sector of 142
Institutional and government
71
Inputs
  • Funds adding, latest quarter213 · 85 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$260K · 57 pct, sector of 50
Risk and compliance
56
Inputs
  • Short interest, % of float+25.5% · 2 pct, sector of 240
  • Recalls per $1B revenue, 3y0.00 per $1B · 100 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+7.9% · 65 pct, sector of 198
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

TMDX filings, in plain words

Are TransMedics insiders buying or selling TMDX?

In the 180 days to 2026-10-27, TransMedics insiders were net sellers, a net $613.3K: $109.1K of purchases and $722.4K of sales reported on Form 4, by 1 buyer and 1 seller.

Read the full summary

In the 180 days to 2026-10-27, TransMedics insiders were net sellers of TMDX, a net $613.3K across purchases and sales reported on Form 4 by 1 buyer and 1 seller. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies